CD274 and pancreatic ductal adenocarcinoma: Monotherapy using anti-PD-1 or anti-PD-L1 antibody could also boost systemic T cell expansion, trigger objective responses, and convince the persistent neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma (PDA) murine model [83].